ArticleBMC immunology2025

Incidence of severe adverse events in cancer patients after treatment with immune-checkpoint inhibitors during the COVID- 19 pandemic.

Sakiko Kimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.